Critics Decry Trump’s Selection of Heidi Overton to Lead FDA

Trump announced the nomination on Truth Social, framing the physician and former America First Policy Institute staffer as a key figure to execute a transformative health agenda. She is slated to replace former commissioner Marty Makary, who resigned in May. The administration intends for Overton to work alongside CMS Administrator Mehmet Oz to push for accelerated drug approvals and clinical trial reforms.

Opposition to the appointment centers on fears that Overton will compromise the agency’s scientific independence. Reproductive Freedom for All blasted the nomination, citing her celebration of the overturning of Roe v. Wade and her previous work advocating for restrictions on mifepristone. Critics argue her history of pushing medically unnecessary hurdles for abortion access suggests an intent to weaponize the FDA for ideological ends.

Her record on vaccines has also drawn intense focus. While Overton previously supported Operation Warp Speed, she later pivoted to oppose school mandates. Her recent involvement in an executive order to split the measles, mumps, and rubella vaccine into separate components has sparked alarm among public health experts. Senator Bill Cassidy (R-La.), chair of the Senate Health, Education, Labor, and Pensions Committee, publicly questioned her managerial experience and commitment to sound science, calling her role in the vaccine directive “almost disqualifying.”

These concerns emerge as the FDA remains in a state of flux following significant staff departures under Health and Human Services Secretary Robert F. Kennedy Jr. Industry analysts have expressed skepticism regarding her qualifications, with some suggesting the agency faces further instability under her leadership.